Prostate Cancer Genomic Classifier VL

Personalized Hormone Therapy with Post-Operative Radiation Therapy and Validation of the Decipher Genomic Classifier in SAKK 09/10 Trial - Dan Spratt and Alan Dal Pra

In this UroToday presentation Daniel Spratt, MD, and Alan Dal Pra, MD, share results from recent clinical trials that highlight the timing and patient selection for the personalization of hormone therapy with postoperative radiation therapy and the clinical implications for Decipher. Biographies: Daniel Spratt, MD, Vincent K. Smith Chair in Radiation Oncology, University Hospitals Seidman Cancer C...

When to Add ADT to Early or Late Salvage Radiation - Dan Spratt

Daniel Spratt, MD, reviews the data from two trials that demonstrate the selection of patients for the addition of hormone therapy (ADT) to post-prostatectomy radiation therapy. Dr. Spratt discusses two phase three trials that have evaluated hormonal therapy in the postoperative RP setting with a rising PSA. The RTOG 9601 trial and the GETUG-AFU 16 trial are distinct from each other where the RTOG...

Clinical Case Discussions - "Rising PSA 18 Months Post RP and Timing of Radiotherapy" - Ashley Ross, Alan Dal Pra, and Dan Spratt

Ashley Ross, MD, PhD, Alan Dal Pra, MD, and Daniel Spratt, MD, discuss two cases of patients each about 18 months post-prostatectomy with rising PSA, evaluating the timing to radiotherapy and the evidence to intensify with ADT. Biographies: Ashley Ross, MD, Ph.D., Associate Professor, Department of Urology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois Alan Dal Pra, MD, A...
email news signup